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Summary 
The in vivo administration of certain monoclonal antibodies (mAbs) against the adhesion receptor, 
CD44, into normal mice induces both a modulation of CD44 from the surface of peripheral 
lymphocytes, and a concomitant increase in the amount of soluble CD44 in the serum. CD44- 
negative lymphocytes isolated from anti-CD44-treated mice exhibit normal homing patterns upon 
adoptive transfer, and are capable of reexpressing CD44 upon activation. The treatment of hapten- 
sensitized mice with anti-CD44 mAb inhibits their ability to mount a cutaneous delayed-type 
hypersensitivity (DTH) response within the first 24 h after hapten challenge.  This inhibition 
reflects a block in both the edema and leukocyte infiltration of the cutaneous site of DTH, whereas 
the extravasation and accumulation ofleukocytes in the draining lymph nodes progress normally. 
After 72 h, the leukocytes that extravasate into the site of antigen challenge express CD44. These 
results indicate that CD44 is not necessary for normal leukocyte circulation but is required for 
leukocyte extravasation  into an inflammatory site involving nonlymphoid tissue. 
C 
D44  (pgp-1) is a type I  transmembrane glycoprotein 
found on the surface of most leukocytes, fibroblasts, ker- 
atinocytes,  and epithelial cells. The principal, known ligand 
for CD44 is the glycosaminoglycan, hyaluronic acid (HA), 1 
a major constituent of extracellular matrices (1-4).  CD44 is 
thought to play a role in several processes critical to normal 
immune system development and function, including leuko- 
cyte extravasation, myelo- and leukopoiesis, and leukocyte ac- 
tivation (5-7). In addition, recent evidence has demonstrated 
that CD44 and its alternatively spliced isoforms (CD44R) 
endow some tumor cells with enhanced metastatic proclivity 
(8-15). Many of these functions may be mediated by interac- 
tions between CD44 and HA (1, 16); however, other counter- 
receptors for CD44 may exist,  for example on endothelial 
cells (17, 18). 
Several lines of in vitro evidence have suggested that CD44 
promotes the binding of lymphocytes to specialized or high 
endothelial venules (HEVs), which support the extravasation 
of circulating lymphocytes from the blood into lymphoid 
organs (5, 9,  16). However, efforts  to confirm the impor- 
tance of CD44 in lymphocyte extravasation  in experimental 
1Abbreviations used in  this paper: DNFB, 2,4-dinitro-l-fluorobenzene; 
DTH,  delayed-type  hypersensitivity;  ECM,  extracellular  matrix; 
HA, hyaluronic acid; HEV, high endothelial venule; PLN, peripheral 
lymph node. 
animals, or to define novel roles for CD44, have been ham- 
pered by the lack of anti-CD44 mAbs that block specific func- 
tions. Miyake et al. (1) have described an anti-murine CD44 
mAb that inhibits the interaction between CD44 and HA; 
however, this antibody fails to block the binding of lympho- 
cytes to HEVs (2). CD44-deficient mice have yet to be devel- 
oped through genetic manipulation. 
To study the role of CD44 in the periphery of mature 
animals,  we injected hapten-sensitized mice with various 
CD44-specific  mAbs, and analyzed their capacity to mount 
a delayed-type hypersensitivity (DTH) reaction. During the 
course of these experiments we discovered that the in vivo 
administration of certain mAbs to CD44 results in the com- 
plete modulation of CD44 from the surface of lymphocytes 
in the peripheral lymph nodes (PLN) and blood, and a sub- 
stantial  decrease in CD44 expression  from lymphocytes in 
the spleen and mesenteric lymph nodes. In contrast to ex- 
isting evidence from in vitro experiments, these CD44-negative 
cells are equally as adept at entering both peripheral and 
mucosal lymphoid organs upon adoptive transfer as CD44- 
positive cells from control mice. However, CD44-deficient 
mice exhibit a marked reduction in the inflammation associated 
with the early stages of a cutaneous DTH response.  In par- 
allel experiments, mAbs specific for LFA-1 inhibited normal 
lymphocyte homing and ablated both the early and late phases 
of the cutaneous DTH response (19). Unlike anti-LFA-1 treat- 
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cells found in the lymph nodes draining DTH sites. These 
results dearly distinguish the functions of CD44 and LFA-1 
in leukocyte trafficking, and suggest that CD44 may be im- 
portant  in mediating the extravasation of leukocytes into 
inflamed nonlymphoid tissue, but that it is not critical for 
normal leukocyte migration into lymphoid organs. 
Materiah and Methods 
Production and Purification of raAbs.  The following anti-mouse 
mAbs were used in this study: 2Cll (CD3, hamster) (20), obtained 
from American Type Culture Collection (ATCC; Bethesda, MD); 
IM7 (CD44, rat IgG2b) (21), a generous gift of I. Trowbridge (Salk 
Institute, La  JoUa, CA); KM201 (CD44, rat IgG1) (7), a generous 
gift of  P. Kincade (Oklahoma Medical  Research Foundation, Okla- 
homa City, OK); IRAWB14.4 (CD44, rat IgG2a) (22), a generous 
gift ofJ. Lesley  (Sulk Institute); 23G2 (CD45Rz, rat IgG2a) (23), 
produced by M. Birkeland and E. Put6 (The Rockefeller Univer- 
sity, New York, NY); YN-1/1.7.4 (ICAM-I [CD54], rat IgG2b) 
(24), obtained from ATCC; Md-14 (L-selectin, rat IgG2a) (25); 
FD441.8 (LFA-1 [CDlla/CD18], rat IgG2b) (26), obtained from 
ATCC; M1/70 (MAC-1 [CD11b/CD18], rat IgG2b) (27), obtained 
from ATCC. 
Hybridoma ceils were expanded in RPMI 1640 (Gibco Labora- 
tories, Grand Island, NY) supplemented  with 10% heat-inactivated 
FCS (Hazelton Biologics,  Lenexa,  KS), antibiotics,  antimycotic,  and 
t-glutamine. Cells in log-phase growth were washed free of FCS 
and grown to maximal density in serum-free medium containing 
Nutridoma-S1  ~  (Boehringer  Mannheim Biochemicals,  Indianapolis, 
IN). Antibody was purified by precipitation with ammonium sul- 
fate (50% saturation), dialyzed against PBS, and filter sterilized. 
Animals and raAb Administration Protocols.  8-20-wk-old female 
CD2Ft (BALB/c x  DBA/2)F1 mice were purchased from The 
Trudeau Institute  (Saranac Lake, NY).  Mice were injected in- 
traperitoneally with various concentrations of mAb or normal rat 
IgG (Jackson ImmunoResearch, West Grove, PA) diluted in iso- 
tonic saline to 1 mg/ml. 
In Vivo CellMigration Assay.  Peripheral  lymph node cells were 
removed from mice treated (intraperitoneaHy) for 12-24 h with 
the anti-CD44 mAb IRAWB14 (300/~g),  the anti-LFA-1 mAb 
FD441.8 (200/~g), or normal rat IgG (300/zg). 107 cells were sus- 
pended in 1 ml HBSS containing 5 /~g mindium oxyquinoline 
(Amersham Clinical Products, Arlington Heights, IL) for 30 min 
at "~25~  Cells were washed twice with complete medium con- 
taining 20% FCS, twice with medium with 10% FCS, and once 
with isotonic saline. Cells (0.1-0.3 cpm/cell) were resuspended at 
107/ml, and 300 #1 0  x  106 cells) was injected into the tail veins 
of normal mice. 1-18 h later, mice were anesthetized by exposure 
to methoxyflurane (Metofane|  Pitman-Moore, Mundelein, IL), 
and peripheral blood was recovered by retro-orbital bleeding be- 
fore death. Organs were removed, weighed, and assayed  for their 
incorporation of radiolabeled cells using an auto-gamma scintilla- 
tion spectrometer (5220; Packard Instrument Co., Inc., Downers 
Grove, IL). 
Generation and Evaluation of  DTH Responses.  20/~1  of  0.5% 2,4- 
dinitro-l-fluorobenzene (DNFB) (Sigma Chemical Co., St. Louis, 
MO) in 4:1 acetone:olive oil (Sigma Chemical Co.) was painted 
on the rear footpads of mice for a successive 2 d. 4 d later, mice 
were challenged by applying 10/L1 of 0.2% DNFB (in the same 
vehicle) to each side of each ear. In each experiment, unsensitized 
mice, painted only with the vehicle on their footpads at the time 
of sensitization, and later challenged  with DNFB on the ears, were 
included as controls. Ear thickness was measured before challenge 
and at 24, 48, and 72 h postchallenge, using an engineer's microm- 
eter (Mitutoyo Co. Mfg. Ltd., Tokyo,  Japan). Each ear was mea- 
sured twice, for a total of four measurements per animal. 
Isolation of Leukocytes.  Cells  were isolated from lymph nodes 
and spleens by teasing, and the resulting cell suspensions were 
washed, counted,  and analyzed as described. Splenocytes were 
depleted of RBC by incubating them for 2 min in a solution of 
10 mM Tris/HC1, pH 7.5, 0.17 M NH4C1 at "~25~  Peripheral 
blood leukocytes were partially purified from heparinized blood 
by adding one-half volume 2%  dextran T500 (Pharmada Fine 
Chemicals, Piscataway, NJ) in PBS, and allowing RBC to ag- 
glutinate and settle for 30 rain. The RBC-depleted cell suspension 
was centrifuged and the resulting pellet treated with RBC lysis 
buffer as above. 
In Vitro Stimulation of Lympkocytes.  Partially  purified cell sus- 
pensions from PLN were incubated in complete medium for 12 h 
at a density of 4  x  106 cells/m1, in the presence or absence of 100 
ng/ml phorbol dibutyrate and the anti-CD3 mAb, 2Cll (25% 
[vol/vol] culture supernatant). Where indicated, cells were addi- 
tionally treated with 0.1/~g/ml actinomycin-D  (Sigma Chemical 
Co.) or 2.5/~g/ml cyctoheximide (Sigma Chemical Co.). 
Fluorescence Flow Cytometry.  For unconjugated antibodies, cells 
were incubated for 30 min with 5-10/~g/rnl purified antibody or 
culture supernatant (30% [vol/vol]) diluted in PBS containing 1 
mg/ml BSA and 0.02% sodium azide. Cells were then stained  with 
F(ab')2  FITC-conjugated  mouse  anti-rat  IgG  (Jackson Im- 
munoResearch Labs., Inc., West Grove, PA), washed, fixed with 
3.7% formaldehyde,  and analyzed on a FACScan  |  (Becton Dick- 
inson & Co., Mountain View, CA). For double labeling, calls  were 
incubated with PE-conjugated antibodies against CD4 or IgD, in 
combination  with FITC-conjugated  antibodies against CD44 (IM7) 
or CD8.  Cells were fixed and analyzed as above. To distinguish 
viable from nonviable  ceils, unfixed  cells were treated with 5/~g/ml 
ethidium bromide immediately before analysis. 
Radioimmunoassay.  Flexible  microtiter plates were coated with 
the anti-CD44 mAb, KM201 (20/~g/ml) for 3 h at room tempera- 
ture (RT). Plates were washed with H~) and quenched with PBS 
containing 0.2% BSA (PBS/BSA) for 1 h at RT. Serum was pre- 
pared from the dotted, nonheparinized blood of mice previously 
treated for 12 h with normal rat IgG, an anti-LFA-1  mAb (FD441.8), 
or anti-CD44 mAbs (IRAWB14 and IM7). Serum samples were 
clarified  by centrifugafion, seriaUy  diluted in triplicate  in PBS/BSA, 
and added to the plates for 2 h at RT. Plates were washed with 
HzO, and 106 cpm/ml of lmI-labeled IM7 (anti-CD44) (sp act, 
'~1.1  x  107 cpm//~g) was added for  1.5 h at RT.  Plates were 
washed, dried, and individual  wells were cut and counted separately 
using an auto-gamma scintillation spectrometer (5220; Packard In- 
strument  Co., Inc.). 
Imraunohisto- and Imraunocytocheraical  Staining.  Tissue  specimens 
were kept in RPMI or Histocon  |  (HistoLab,  Gothenburg, Sweden) 
at 4~  (for <8 h) until they were snap-frozen  in chilled isopentane 
and stored at -80~  Acetone-fixed,  6-/~m-thick  cryostat sections 
or cytospin  preparations of  lymph node cells  were incubated  in 0.3% 
HzOz in PBS for 15 rain at RT to block endogenous peroxidase, 
and then reacted with normal rabbit serum (diluted 1:10) for 10 
rain to reduce nonspecific  staining. Binding of  rat mAbs was visual- 
ized with biotinylated rabbit anti-rat IgG (2.5/~g/ml) and avidin- 
biotin-peroxidase  complexes  (Vectastain  ABC  |  kit; Vector Labora- 
tories, Inc., Burlingame, CA). The peroxidase reaction was devel- 
oped with 3',3' diaminobenzidine  tetrahydrochloride  (Polysciences, 
Inc., Warrington, PA). The sections and cells were counterstained 
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(Merck, Darmstadt,  Germany). The optimal dilutions of the anti- 
bodies were determined by using sections  from normal spleen, lymph 
nodes, and skin. Each ear specimen was also processed for hema- 
toxylin and eosin staining. 
Results 
Anti-CD44 mAbs Induce the Modulation of  CD44  from Lym- 
phocytes In Viw  The intraperitoneal injection of the anti- 
CD44 mAbs IRAWB14 or IM7 induces a striking reduction 
in the amount of cdl surface CD44 expressed on lympho- 
cytes in the periphery as determined by fluorescence-activated 
flow cytometry and immunohistochemistry. This reduction 
is obvious at 5 h postinjection, and maximal at 12-24 h (Fig. 
1). Cells isolated from PLN bear no detectable CD44 on their 
surfaces by 12 h postinjection. Mesenteric lymph node cells 
exhibit nearly complete modulation, whereas splenocytes re- 
tain *50% of their CD44 (Fig. 1). The overall number of 
cells as well as the percentage of IgD + B cells,  and CD4 + 
and CD8 §  T  cells,  in peripheral lymph nodes are not af- 
fected by anti-CD44 mAb treatment (Table 1, and data not 
shown). Peripheral blood B and T ceils are also CD44 nega- 
tive, and the number of circulating leukocytes was similar 
in antibody-treated and control animals (Fig. 2, and data not 
shown). The varying extent of CD44 modulation in different 
lymphoid organs may reflect distinctions in the subpopula- 
tions of lymphocytes residing in each.  Alternatively, there 
may be a difference in the efficiency of  mAb delivery to different 
lymphoid organs after intraperitoneal administration. In view 
of this distinction, all adoptive transfer experiments in this 
study were carried out with PLN cells. In mice treated with 
isotype-matched mAbs  to  two other adhesion molecules, 
LFA-1 and ICAM-1, the antibodies remain associated  with 
the surface of LFA-l-positive leukocytes and ICAM-l-positive 
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Figure  I.  The in vivo administration of anti-CD44 mAbs modulates 
CD44 from the surface of lymphocytes.  Cells were isolated from the pe- 
ripheral and mesenteric  lymph nodes and spleens of normal mice (0 h) 
or normal  mice  injected  (300  #g i.p.)  with the anti-CD44  mAbs IRAWB14 
or IM7 (5 and 12 h). Cells were then stained with the anti-CD44 mAb 
KM201, visualized  with a FITC-conjugated  secondary  antibody, and ana- 
lyzed by fluorescence  flow cytometry. 
leukocytes and endothelial cells, respectively (19), suggesting 
that  the downregulation of CD44 expression occurs by a 
specific mechanism. 
We analyzed the cell surface phenotype of CD44-negative 
lymphocytes from anti-CD44-treated mice using a panel of 
mAbs against a variety of surface antigens, including adhe- 
sion receptors and activation markers (Fig.  3). The removal 
of CD44 from the surface of lymphocytes does not result 
in the comodulation of the other cell surface receptors ana- 
lyzed (LFA-1,  ICAM-1, L-sdectin, CD4,  CD8,  and IgD), 
nor does the activation state of these lymphocytes appear to 
Table  1.  Anti-CD44 mAb  Treatment Does Not Reduce the Number of Cells in Pe@heral Lymph Nodes 
Exp.  Treatment  Antibody  Dose  Cells/PLN 
A  Normal,  unsensitized 
B  DNFB unsensitized,  challenged 
DNFB sensitized and challenged 
#g  xl06 
Normal rat IgG  300"  2.1 
IRAWB14  300  2.0 
FD441.8  200  1.3 
-  -  2.2  _+  0.7 
Normal rat IgG  400*  6.7  _+  0.6 
iRAWB14  400  6.2  +  0.8 
IM7  400  6.8  _+  0.4 
Leukocytes  were removed  from the PLN of normal mice, or the draining lymph nodes of DNFB-chaUenged  mice (unprimed or DNFB sensitized). 
In exp. A, lymph nodes were removed  24 h after antibody injection, whereas in exp. B they were harvested 24 h after DNFB challenge on the 
ears (see Fig. 8). Lymph nodes were placed in culture medium on ice and gently teased. The resulting ceUs were counted using a hemocytometer 
and checked for viability  by trypan blue exclusion. In all cases viability  was >75%. Results shown are from typical experiments and are expressed 
as the number of cells per lymph node based either on cell counts from a combined  pool of 30-36 lymph nodes from  five to six mice in each group 
(exp. A), or cell counts from four individual draining lymph nodes isolated from two mice in each group (exp. B). 
* Administered 12 h before death. 
* Administered 20 h (300 #g) and 1 h (100/~g) before challenge (see Fig. 8). 
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Figure 2.  Treatment with anti-CD44 mAb modulates CD44 from the 
surface of peripheral blood B and T cells. Blood was removed from saline- 
treated (untreated) mice or mice treated for 12 h with 300 #g anti-CD44 
mAb IRAWB14 (anti-CD44 R~). Enriched suspensions of leukocytes were 
prepared according  to Materials and Methods.  Cells were double labeled 
with a combination of PE-conjugated  anti-CD4 or anti-IgD and FITC- 
conjugated  anti-CD8 or anti-CD44 (IM7).  Cells were gated for CD4 + 
T cells or IgD * B cells, and analyzed for their expression of CD44 or 
CD8 (negative control). 
be different based of the expression of CD45R,  B (Fig. 3, and 
data not shown) (23, 28). 
Anti-CD44  mAb Treatment Induces the Shedding of CD44 
into the Serum.  To gain insight into whether internalization 
or shedding accounted for the modulation of CD44 from 
the surface of lymphocytes,  we analyzed acetone-fixed and 
permeabilized  tissue  sections  of PLN  from  mAb-treated 
animals, for cell-associated CD44 (Fig. 4). When probed for 
the presence of the injected anti-CD44 mAb, using a poly- 
clonal anti-rat Ig antibody, most lymphocytes in the PLN 
are devoid of CD44;  however, a subpopulation  of cells that 
do not appear in single-cell suspensions prepared from lymph 
nodes (Fig. 3) are intensely stained (Fig. 4). These cells may 
consist of dendritic cells, fibroblasts, macrophages,  and/or 
interdigitating cells. To detect all CD44, including that not 
bound by the in vivo administered mAb, we stained the sec- 
tions with an anti-CD44 mAb followed by secondary anti- 
body. This analysis fails to reveal any additional CD44 (Fig. 
4). Analysis of acetone-fixed cytospin preparations of isolated 
lymphocytes reveals similar results (data not shown). How- 
ever, internalized, significantly degraded CD44 or anti-CD44 
could presumably escape detection using these techniques. 
Given the lack of evidence for internalized CD44 or anti- 
CD44 immune complexes in lymphocytes, we analyzed the 
levels of soluble CD44 found in the serum of anti-CD44- 
treated  and control mice, using a sandwich  RIA (Fig. 5). 
Serum from control animals and humans contains significant 
levels of soluble CD44 (Fig. 5) (29). IRAWB14-treated mice 
exhibit a 1.5-2-fold increase in serum CD44 levels, consis- 
tent with mAb-induced shedding of CD44 (Fig. 5). We could 
not detect high levels of soluble CD44 in the serum of IM7- 
treated animals using 12SI-labeled IM7,  suggesting that the 
injected antibody remains complexed with shed CD44 (data 
not shown). We have not yet determined the mechanism of 
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Figure  3.  The cell surface phenotype of CD44-positive and  CD44- 
negative lymphocytes.  Lymphocytes were isolated from the PLN of mice 
treated  for 12 h with 300 #g normal rat IgG (N. Rat IgC Rx) or IM7 
(anti-CD44 Rx), and stained with mAbs to the indicated surface antigens. 
mAb binding was visualized with a FITC-conjugated  secondary antibody, 
and  analyzed by fluorescence flow cytometry. 
shedding of CD44 induced by anti-CD44 mAb in vivo; how- 
ever, our data are consistent with results from a recent study 
that demonstrated a partial shedding of CD44 from cells in- 
duced by in vitro exposure to immobilized anti-CD44 (30). 
The Reexpression of CD44 Requires Lymphocyte Activation. 
CD44-negative lymphocytes explanted from the PLN of  mice 
12 h post-mAb injection fail to reexpress CD44 on their sur- 
face after a 12-20-h culture in vitro in the absence of stimu- 
500  Role of CD44 in Leukocyte Homing Figure  4.  In situ analysis of CD44 expression  in PLN of mice treated  with anti-CD44 mAb. DNFB-sensitized mice were injected  with 300/zg 
i.p. of IRAWB14 (anti-CD44 R~) or a control (N-Rat lgG R~) and challenged with DNFB 2 h later. After 24 h, draining lymph nodes were removed 
and acetone-fixed cryostat  sections prepared.  Sections were stained with secondary antibody alone (No Pn'mary), or IRAWB14 followed by secondary 
antibody (anti-CD44). 
lant (Fig.  6). However, stimulation with a combination of 
phorbol esters and a mitogenic anti-CD3 mAb enhances the 
expression of CD44 on CD44-positive cells (from control 
mice) and induces CD44 expression on CD44-negative cells 
(from mAb-treated mice), resulting in similar levels of ex- 
pression on the two populations. The enhanced expression 
on cells from control mice and the reexpression of CD44 on 
cells from anti-CD44-treated animals are completely blocked 
by cycloheximide, which inhibits protein synthesis.  PCR 
amplification of the mKNA from CD44-negative cells demon- 
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Figure  5.  The administration  of anti-CD44 mAbs in vivo results  in 
increases in the level of CD44 in the serum of mice. Serum from normal 
mice treated  for 12 h  with 300/zg control antibodies  (N. rat IgC Rx) 
or  200  #g  FD441.8  (anti-LFA-1 Rx),  or  300  #g  anti-CD44  mAbs 
(IRAWB14),  was analyzed in a sandwich RIA using plate-bound  KM201 
and  12SI-labeled IM7.  Lysate from normal PLN cells was used as a posi- 
tive control.  Results expressed are the average of serum samples from three 
to four mice  _+  SEM,  subtracted  from a background mean of 62 cpm. 
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strates that these cells retain CD44-specific mRNA (data not 
shown). Resting T  cells express little, if any, CD44R (12, 
13), and the elevated expression of CD44 after T cell activa- 
tion, as detected by the mAbs used in this study, is primarily 
due to the enhanced expression of CD44, not CD44R (Camp, 
R. L., and E. Pur6, unpublished observations).  Below,  we 
also describe evidence for activation-induced reexpression of 
CD44 in vivo. 
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Figure  6.  The stimulation  of CD44-negative T cells in vitro induces 
the expression of  CD44. Lymphocytes were isolated from the PLN of  normal 
mice treated for 12 h with 300/zg N. rat IgG (Control)  or 300/zg IRAWB14 
(anti-CD44 R~). Calls were cultured for 12 h in the absence (No stimu- 
lant) or presence of a combination of phorbol ester and an activating anti- 
CD3 mAb, 2Cll (PDBU/~CD3).  Cells were coincubated  in the absence 
(no add) or presence of cycloheximide (cyclokex). Viable cells were selected 
according to their ability to exclude ethidium bromide,  and their expres- 
sion of  CD44 was analyzed with a FITC-conjugated anti-CD44 mAb (IM7). 0 
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Figure  7.  The  migratory  pat- 
terns of CD44-negative and CD44- 
positive  lymphoeytes  in  normal 
mice.  Lymphocytes  were  isolated 
from the PLN of normal mice in- 
c~  jetted with 300 ~g normal rat IgG, 
"o  200 /zg FD441.8  (anti-LFA-1), or 
300/~g IRAWB14 (anti-CD44)  12 h 
O  before death. Cells were hbeled in 
vitro with rain, washed,  and in- 
~,  jected into the tail veins of normal 
mice (3  x  10  ~ cells/mouse).  1-18 h 
posttransfer,  injected  mice  were 
c~.  killed, their organs weighed, and the 
o~"  amount  of  incorporated  radioac- 
tivity was measured. Each data point 
represents an average  of results from 
two mice + SEM. To normalize for 
--,  variability between mice, results are 
expressed as the percentage of total 
radioactivity recovered per organ, 
divided'by the orgaffs  weight in 
grams. The absence of error bars for 
some  data points  indicates  error 
values that are too small to be visual- 
ized graphically. MLN, mesenteric 
lymph node; PP, Peyer's patch; SPL, 
spleen. 
CD44-negative Lymphocytes Home to Pe@heral and Mucosal 
Lymphoid Organs.  To determine the homing potential of 
CD44-negative  lymphocytes,  we isolated  PLN  cells  from 
normal mice injected with mAbs against CD44 or LFA-1, 
or normal rat IgG. These cells were analyzed by flow cytom- 
etry and determined  to be CD44 negative,  saturated with 
LFA-1, or CD44 positive,  respectively  (Fig.  3, and data not 
shown). The cells were subsequently labeled with mindium, 
washed and injected intravenously  into normal mice.  Mice 
were killed I or 18 h later and various organs were removed, 
weighed, and assayed for the presence of labeled cells. Lym- 
phocytes from untreated  or control mice,  injected  in this 
manner, are initially trapped in the lungs, and subsequently 
disseminate to the peripheral and mesenteric lymphoid organs 
and the spleen (Fig.  7). After 18 h, the vast majority  of la- 
beled cells has marginated from the blood into other tissues 
(Fig. 7). The specificity of this extravasation is demonstrated 
by the lack of cell accumulation in highly vascularized tissues 
(i.e.,  lung, liver, and kidney). 
We and others have previously determined that cells coated 
with an anti-LFA-1 mAb migrate normally to nonlymphoid 
organs and the spleen, but fail to migrate into the peripheral 
and mesenteric  lymph nodes or the Peyer's patches (Fig.  7) 
(19,  31).  In contrast,  CD44-negative,  unactivated  lympho- 
cytes exhibit migratory patterns identical  to those of lym- 
phocytes from control mice (treated with normal rat IgG), 
in terms of their  ability to extravasate into peripheral and 
mesenteric  lymphoid organs  and spleen  (Fig.  7). To elimi- 
nate the possibility that CD44-negative cells reexpress their 
CD44 in vivo after adoptive  transfer, we performed  similar 
homing experiments using recipient mice that were injected 
with anti-CD44 mAb 12 and 3 h before adoptive  transfer. 
These experiments failed to reveal any significant  difference 
between the migratory patterns of normal and CD44-negative 
lymphocytes (data not shown). 
Consistent with the data above, the number of cells recov- 
ered from the PLN of anti-CD44-treated mice is identical 
to that obtained from control mice, whereas the number of 
cells isolated from the lymph nodes of mice treated with anti- 
LFA-1 is 62% of controls at 24 h post-mAb administration 
(Table 1, exp.  A). 
Treatment with Anti-CD44  mAbs Inhibits the Early Phase of 
the DTH Response.  To investigate  the immune competence 
of hapten-sensitized  mice injected  with anti-CD44 mAbs, 
we analyzed their ability to exhibit DTH in response to hapten 
challenge presented by skin painting. The administration  of 
mAbs against  CD44 before and during antigenic challenge 
delays the onset of DTH by at least 24 h (Fig. 8). Ultimately, 
the peak inflammatory  response is similar to that observed 
in animals injected with control antibody. A histological anal- 
ysis of the DTH sites at 24 h demonstrated  that anti-CD44 
treatment inhibits both the edema and the cellular infiltrate 
associated with early inflammation (Fig. 9). The normal cel- 
lular infiltrate  in a murine DTH  reaction  at  24 h  is pre- 
dominately composed of T lymphocytes (32). Analogous treat- 
ment of mice with mAb to LFA-1  also inhibits the DTH 
response,  but this suppression  is protracted and inhibits at 
both early (<24 h) and late (>48 h) time points (19). Anti- 
LFA-1 mAbs also inhibit the influx of cells into lymph nodes 
draining DTH sites, whereas anti-CD44 mAbs have no effect 
on the number of cells recovered (19,  and Table 1, exp. B). 
The DTH response in sensitized mice given a single dose 
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Figure  8.  The administration  of anti-CD44 mAbs in vivo inhibits  the 
early phase of  DTH responses. DNFB-sensitized  mice (six per group) were 
injected with 300 #g control antibody (N. rat IgG) or 300 #g of anti- 
CD44 mAb (IM7 or IRAWB14) at the indicated  times. Mice were chal- 
lenged on the ears with DNFB, and mean ear swelling  was determined 
24-72 h later. DNFB-challenged, unsensitized  mice were used as a nega- 
tive control (Unsensitized). Two animals in each group were killed at 24 
and 72 h, and organs were taken for further analysis. Results are expressed 
as the increase in ear thickness  (mean value of both ears measured at the 
indicated times postchallenge minus mean value before challenge) _+ SEM. 
The anti-CD44-treated animals  showed a reduced ear swelling  that was 
statistically significant at 24 h postchallenge  (iv < 0.0005,  student's  t test) 
compared  with N.  rat  IgG injected  animals. 
(300 #g)  of anti-CD44 mAb 12 h before hapten challenge 
is similarly suppressed (data not shown). In contrast, the ad- 
ministration of mAbs against CD44 (including KM201, which 
blocks CD44/HA  interactions)  1-3 h before challenge  has 
little effect on the resulting DTH response (data not shown). 
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Figure  10.  Lymphocytes  in the lymph nodes draining DTH sites re- 
main CD44 negative. Leukocytes were isolated from the draining lymph 
nodes of the mice analyzed in Fig. 8, at the 72-h time-point. Cells were 
stained  with a FITC-conjugated anti-CD44 mAb (KM201). 
Given that we have established that the modulation of CD44 
from the surface of lymphocytes in vivo takes at least 12 h 
(Fig.  1),  this result suggests  that  CD44 modulation must 
occur before challenge to achieve an inhibition of the DTH 
response. 
The delay in the presentation of a full-scale DTH response 
in anti-CD44-injected animals might imply that CD44 ex- 
pression is required only during the early phase of DTH, and 
that CD44-negative cells could extravasate during the later 
phase of the response. Alternatively, the delay may represent 
the time required for cells  to become activated and subse- 
quently reexpress CD44 on their surface, after  which the DTH 
response would proceed normally. To investigate these possi- 
bilities,  we looked at the expression of CD44 on lympho- 
cytes in both DTH-inflamed skin and the adjacent draining 
lymph nodes at 72 h. The vast majority of lymphocytes  iso- 
lated from the draining lymph nodes at 72 h remain CD44 
negative, although a small number of cells is CD44 positive 
(Fig.  10). In contrast,  those leukocytes that eventually gain 
entrance to the DTH site (by 72 h postchallenge)  are CD44 
positive  (Fig.  11). These cells may represent CD44-positive 
cells that have escaped CD44 modulation and migrated into 
Figure  9.  Anti-CD44 mAb treatment reduces both the edema and cell infiltration  at DTH sites. Hematoxylin- and eosin-stained cryostat  sections 
of ears 24 h after DNFB challenge  of an unsensitized  mouse,  a sensitized mouse given control antibody (N. Rat lgG Rx),  or a sensitized mouse in- 
jected with IM7 (anti-CD44 Rx) before chaUenge (see Fig. 8 for doses and times of injections).  Shown are cross-sections of comparable  areas of ears 
at identical  magnifications. 
503  Camp et al. Figure  11.  Lymphocytes  in the site of DTH are CD44 positive in the late phase of the response. Cryostat sections of ears from mice 72 h  after 
DNFB challenge were stained with an anti-CD44 mAb (IM7).  Shown are ears from an unsensitized  mouse and a sensitized mouse injected with IM7 
(see Fig. 8 for doses and times of injections). The sections are counterstained  with Mayer's hematoxylin.  In addition to infiltrating  lymphocytes, keratino- 
cytes are also CD44 positive  in both sections. 
the DTH site, or lymphocytes that have been activated dis- 
tally or locally and reexpress CD44. The presence of CD44R 
on the surface of keratinocytes (8) may explain the resistance 
of  these  cells  to  anti-CD44-induced  CD44  modulation 
(Fig.  11). 
Discussion 
In vitro studies have defined several potential functions for 
CD44; however, the extent to which these activities are im- 
portant in vivo is unknown. There is mounting evidence to 
suggest that CD44 and its associated isoforms (CD44R) play 
a central role in the cell adhesion and migration of primary 
leukocytes and the metastatic proclivity of certain tumors 
(8-13).  HA, a glycosaminoglycan found ubiquitously as an 
extracellular matrix (ECM) component, is the principal ligand 
defined for  CD44.  Of particular  interest  in  view of our 
findings, is the presence of HA as a component of the ECM 
of the vascular intima and the accumulation of HA in inflam- 
matory lesions  (33-35). 
Several studies have suggested that CD44 may play a role 
in the extravasation  of lymphocytes into lymphoid organs, 
in part through a putative glycoprotein ligand ("addressin") 
expressed on HEVs (17). In humans, an anti-CD44 mAb, 
Hermes-III, blocks the binding of lymphocytes to the HEVs 
on tissue sections of mucosal lymphoid organs.  Hermes-III 
also partially blocks the binding of activated T cells to IL- 1- 
stimulated human umbilical vein endothelial cells (36).  In 
addition, a polydonal serum against CD44 blocks the binding 
of lymphocytes to PLN HEVs and inflamed synovia  (5). 
The initial binding of lymphocytes to HEVs appears to 
be independent of CD44/HA interactions (2). However, other 
studies suggest that CD44 can bind endothelial cells in an 
HA-dependent manner (16, 22). Consequently, the relation- 
ship between HA and the endothelial addressin  is unclear 
(2, 16, 22). HA may be a component of the HEV addressin, 
and/or act as a separate ECM-derived ligand, particularly in 
nonlymphoid tissue. The HA and addressin binding sites on 
CD44 appear to be distinct (2). The close proximity of the 
HA-rich vascular ECM to the vascular cell surface makes it 
difficult to determine the site of lymphocyte-endothelial  in- 
teractions (i.e., cell-cell vs. cell-ECM) in in vitro binding 
assays. 
Our data are inconsistent with the deduction that CD44 
is a lymphoid organ-specific homing receptor (5, 17, 18, 36, 
37).  We find no evidence in vivo that CD44 is critical  for 
the extravasation of unactivated murine lymphocytes  into any 
lymphoid organ during normal trafficking.  Since the cells 
used for the adoptive transfer experiments were stripped of 
CD44, the lack of an effect on lymphocyte migration as de- 
scribed herein is conclusive evidence that the receptor is dis- 
pensable with regard to this function. Resting T cells do not 
express detectable levels of CD44K (12, 13). The lack of an 
effect on lymphocyte homing cannot be attributed to the reex- 
pression of CD44 on adoptively transferred cells because CD44 
reexpression  is not detectable for at least 24 h in vivo, and 
requires lymphocyte activation in vitro. In addition, CD44- 
negative cells adoptively transferred  into host mice treated 
with anti-CD44 mAb before transfer migrate normally. 
The ability to generate lymphocytes devoid of CD44 pre- 
cludes the need for anti-CD44 mAbs specific for functional 
epitopes, which is particularly advantageous considering that 
CD44 appears to contain multiple functional epitopes (1, 5, 
22). In addition, the modulation of CD44/mAb complexes 
from the cell surface also overcomes the potential for mAb- 
coated cells to be bound and opsonized by FcR-bearing cells. 
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primary cells through genetic manipulation (i.e., "knock-out" 
mice). However, this has not been achieved, to our knowl- 
edge. Furthermore, since CD44 may be critical for develop- 
ment, CD44 knock-out mice may not be amenable to inves- 
tigating the role of CD44 in mature mice. We are presently 
investigating whether CD44 is important for long-term leu- 
kocyte recirculation, and whether it is involved in the migra- 
tion of lymphocytes after extravasation  (i.e., the movement 
of different lymphocyte types to their appropriate lymphoid 
compartments). 
Although CD44 is not necessary for the extravasation  of 
lymphocytes into lymphoid organs, we demonstrate that 
CD44 plays a role in the generation of DTH responses. As 
with many other sites of increased cellular migration, such 
as the developing embryonic limb bud (38),  inflammatory 
sites (33),  and around metastatic tumor deposits (33),  the 
deposition of HA within the DTH site is markedly enhanced 
(34, 35). Given that CD44 binds HA, each of these sites is 
a potential area in which to look for CD44 receptor func- 
tion. DTH responses are particularly interesting because they 
involve a cascade of events that may be influenced by CD44. 
DTH responses are dependent upon the prior generation of 
antigen-primed T  cells during the sensitization phase (39, 
40). After challenge, antigen-primed T cells are restimulated 
and release lymphokines (i.e., IFN-'y and IL-2) that promote, 
both directly and indirectly, increased vascular permeability 
and leukocyte activation and extravasation at both the DTH 
site and in the draining lymph nodes (41-43). HA-rich edema 
precedes the cellular infiltrate,  and is maximal by 24 h post- 
challenge (44). The subsequent migration of cells into DTH 
sites in mice is characterized by the early influx of mononuclear 
cells (1-12 h postchallenge), followed by the enhanced ex- 
travasation  of lymphocytes,  neutrophils,  and  eosinophils 
(12-24 h). By 24 h, lymphocytes predominate (32, 44, 45). 
Anti-CD44 treatment could potentially block any of these 
steps, resulting in temporary immunosuppression. However, 
anti-CD44 does not inhibit the facilitated migration of lym- 
phocytes into the draining lymph nodes after antigenic chal- 
lenge. This observation demonstrates that the DTH response 
is initiated even in the presence of anti-CD44 mAb, and im- 
plies that the T cell memory component of DTH remains 
intact, and antigen presentation, T cell activation, and at least 
some cytokine release are not inhibited. In contrast, events 
occurring at the DTH site at 24 h, including the develop- 
ment of edema and the extravasation  of leukocytes,  are in- 
hibited. This may either reflect a direct blockade of leuko- 
cyte extravasation,  or a defect in the activation or cytokine 
production of T cells, PMN, monocytes, and/or NK cells. 
There is in vitro evidence to suggest that CD44 plays a role 
in each of these processes (46-49). The migration of leuko- 
cytes into the DTH site may be blocked by the combined 
effect of an inhibition in HA matrix deposition (edema) and 
the lack of CD44 (HA receptor). Our studies distinguish 
the role of CD44 from that of LFA-1 since mAbs against 
LFA-1 block both the early and late phases of the DTH re- 
sponse and inhibit the extravasation of cells into both normal 
and draining lymph nodes (19, 31). 
The wide-spread expression  of HA and CD44 suggests 
that CD44-HA interactions must be regulated to prevent 
nonspecific cell adhesion. Indeed, the CD44 expressed on many 
cells, including all primary leukocytes tested, fails to bind 
HA in vitro. However, CD44 can be induced to bind HA 
by treating cells with the anti-CD44 mAb IRAWB14.4, sug- 
gesting that the conformation and/or aggregation of CD44 
is important for its adhesive capacity (22). The physiologic 
signals involved in initiating CD44/HA binding are unknown; 
however, it is possible that cytokines released at a site of inflam- 
mation induce CD44 to bind HA. In addition, receptor in- 
teractions between extravasating leukocytes and the vascular 
endothelium may trigger CD44 function, and thus prepare 
the leukocyte for its subsequent transmigration through the 
underlying HA-rich extracellular  matrix. The induction of 
CD44 function may be effected through increases in the level 
of surface expression, and/or changes in the phosphorylation 
and cytoskeletal  association  of CD44,  all of which are as- 
sociated with leukocyte activation (22,  50,  51). 
In summary, our data indicate that CD44 plays a critical 
role in the generation of the early phase of an inflammatory 
response involving nonlymphoid tissue, but does not appear 
to be required for extravasation  of cells from the blood into 
lymph nodes. 
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